MTOR and neoplasm: Metformin is being investigated because its antineoplastic effects through AMPK-mediated or AMPK-independent inhibition of mTOR; it reduces cyclin D1 inhibiting cancer cell proliferation; it also inhibits tumor cell migration and invasion by inhibiting matrix metalloproteinase-9 (MMP-9) expression.